Bupropion
- Generic Name
- Bupropion
- Brand Names
- Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18ClNO
- CAS Number
- 34911-55-2
- Unique Ingredient Identifier
- 01ZG3TPX31
- Background
Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...
- Indication
Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)
- Associated Therapies
- Smoking, Cessation, Weight Loss
Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms
- Conditions
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 1504
- Registration Number
- NCT00332644
- Locations
- 🇺🇸
UW-CTRI Madison Research site, Madison, Wisconsin, United States
🇺🇸UW-CTRI Milwaukee Research site, Milwaukee, Wisconsin, United States
Bio-behavioral Lung Cancer Prevention Program
- Conditions
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- National Institutes of Health (NIH)
- Target Recruit Count
- 555
- Registration Number
- NCT00322205
- Locations
- 🇺🇸
State University of New York, Buffalo, New York, United States
Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- San Francisco Department of Public Health
- Target Recruit Count
- 30
- Registration Number
- NCT00318409
- Locations
- 🇺🇸
San Francisco Department of Public Health, HIV/AIDS Office, San Francisco, California, United States
Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence
- Conditions
- Interventions
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 143
- Registration Number
- NCT00304707
- Locations
- 🇺🇸
ENRM Veterans Hospital, Bedford, Massachusetts, United States
Smoking Cessation Intervention: Effectiveness in Primary Care
- Conditions
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 1346
- Registration Number
- NCT00296647
- Locations
- 🇺🇸
UW-CTRI Milwaukee Research site, Milwaukee, Wisconsin, United States
Treatment of Depression Following Multiple Brain Tests
- Conditions
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 28
- Registration Number
- NCT00296777
- Locations
- 🇺🇸
Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States
Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM)
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 41
- Registration Number
- NCT00285584
- Locations
- 🇺🇸
Bellevue Hospital Center, New York, New York, United States
🇺🇸New York University School of Medicine, New York, New York, United States
Assessment of Bupropion on Cognitive Function and Behaviour in Healthy Volunteers
- Conditions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2007-08-09
- Lead Sponsor
- University Hospital, Montpellier
- Target Recruit Count
- 12
- Registration Number
- NCT00285155
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Montpellier, France
Bupropion for Hospital-Based Smoking Cessation
- First Posted Date
- 2005-12-02
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 85
- Registration Number
- NCT00261170
- Locations
- 🇺🇸
Veterans Affairs Medical Center, San Francisco, California, United States
Effectiveness of Nefazodone and Bupropion in Treating Marijuana Dependent Individuals
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 132
- Registration Number
- NCT00249509
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.